Sarepta reports Q2 adjusted EPS $2.02, consensus $1.16

Reports Q2 revenue $611.1M, cocnensus $531.04M. “We are very pleased that following a rapid review of the safety data, the FDA swiftly recommended that we take the ambulatory patient population off shipment pause and, following that, we have already resumed deliveries. Infusions are taking place for the ambulatory community. We will continue to work with the FDA to define the path and develop the risk mitigation necessary to bring ELEVIDYS back to the non-ambulatory community as well,” said Doug Ingram, chief executive officer, Sarepta (SRPT). “With the temporary pause lifted, the execution of our restructuring, cost savings and plans designed to meet our financial obligations, and with important siRNA readouts expected later this year, we are well positioned to achieve our strategic objective to remain a patient-centric, financially disciplined organization into the next decade and beyond.”